The GVK Biosciences Case Files: Black-And-White Or Shades Of Gray?
This article was originally published in SRA
Executive Summary
OK, first the disclaimer: this isn't a defence of any firm that isn't up to scratch when it comes to quality. Fudging of data is totally unacceptable and non-adherence to good clinical practice (GCP) or good manufacturing practice (GMP) should attract the toughest regulatory action.